Network analysis using Cytoscape has identified PTGS2, PTGS1, NCOA2, ADRB2, SCN5A, RXRA, NCOA1, ESR1, AR, and DPP4 as key targets for the treatment of CHD with BYXD. This evidence concerns the gene AR and coronary artery disorder.